{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T22:52:07Z","timestamp":1768776727182,"version":"3.49.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hypersensitivity pneumonitis (HP) presents with a highly variable clinical course, and traditional treatment includes systemic corticosteroids and strict antigen avoidance. The objective of this study was to evaluate the therapeutic potential of Rituximab in patients with progressive hypersensitivity pneumonitis who do not respond to antigen avoidance and conventional immunosuppressive therapy. In this cohort prospective study, 30 patients with refractory HP were enrolled. Forced Vital Capacity (FVC) was assessed at three time points: six months before Rituximab initiation (M\u2009\u2212\u20096), at treatment initiation (M0), and six months later (M\u2009+\u20096). FVC% predicted significantly declined from (58.57\u2009\u00b1\u200910.9) at M\u2009\u2212\u20096 to (51.03\u2009\u00b1\u200911.06%) at M0 [<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001], but showed a minimal, non-significant drop to 50.1\u2009\u00b1\u200912.7% at M\u2009+\u20096 [<jats:italic>p<\/jats:italic>\u2009=\u20090.405]. The rate of decline slowed markedly post-Rituximab, from \u2212\u20097.54% (M\u2009\u2212\u20096 to M0) to \u2212\u20090.93% (M0 to M\u2009+\u20096). Dyspnea, measured by the mMRC scale, improved from 2.77\u2009\u00b1\u20090.5 at M0 to 1.83\u2009\u00b1\u20090.85 at M\u2009+\u20096 [<jats:italic>p<\/jats:italic>\u2009=\u20090.001]. 6MWD also increased from 258.67\u2009\u00b1\u200977\u00a0m to 307\u2009\u00b1\u200999\u00a0m [<jats:italic>p<\/jats:italic>\u2009=\u20090.001]. There were no reported cases of mortality. Rituximab demonstrates potential as an emerging therapeutic option for patients with treatment-refractory hypersensitivity pneumonitis and is well-tolerated.<\/jats:p>\n          <jats:p>\n            <jats:italic>Trial registration<\/jats:italic>: Retrospectively registered, registration number is NCT07035561, date of registration 16\/06\/2025.<\/jats:p>","DOI":"10.1038\/s41598-025-21463-y","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:29:02Z","timestamp":1760718542000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Rituximab therapy in patients with treatment-refractory hypersensitivity pneumonitis"],"prefix":"10.1038","volume":"15","author":[{"given":"Yosri","family":"Akl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safy Zahid","family":"Kaddah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereen Medhat","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana Kamal","family":"EL Said","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"21463_CR1","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","volume":"202","author":"G Raghu","year":"2020","unstructured":"Raghu, G. et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline. Am. J. Respir Crit. Care Med. 202, e36\u2013e69 (2020).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"21463_CR2","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1164\/rccm.201203-0513CI","volume":"186","author":"M Selman","year":"2012","unstructured":"Selman, M., Pardo, A. & King, T. E. Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am. J. Respir Crit. Care Med. 186, 314\u2013324 (2012).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"21463_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1183\/09031936.00163911","volume":"40","author":"GJ Keir","year":"2012","unstructured":"Keir, G. J. et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur. Respir J. 40, 641\u2013648 (2012).","journal-title":"Eur. Respir J."},{"key":"21463_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1365-2796.2009.02207.x","volume":"267","author":"F Perosa","year":"2010","unstructured":"Perosa, F., Prete, M., Racanelli, V. & Dammacco, F. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. J. Intern. Med. 267, 260\u2013277 (2010).","journal-title":"J. Intern. Med."},{"key":"21463_CR5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.chest.2021.03.067","volume":"160","author":"ER Fern\u00e1ndez P\u00e9rez","year":"2021","unstructured":"Fern\u00e1ndez P\u00e9rez, E. R. et al. Executive summary: diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 160, 595\u2013615 (2021).","journal-title":"Chest"},{"key":"21463_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thx.54.7.581","volume":"54","author":"JC Bestall","year":"1999","unstructured":"Bestall, J. C. et al. Usefulness of the medical research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54, 581\u2013586 (1999).","journal-title":"Thorax"},{"key":"21463_CR7","doi-asserted-by":"publisher","first-page":"106146","DOI":"10.1016\/j.rmed.2020.106146","volume":"172","author":"M Ferreira","year":"2020","unstructured":"Ferreira, M. et al. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): a retrospective, multicentric, observational study. Respir Med. 172, 106146 (2020).","journal-title":"Respir Med."},{"key":"21463_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo, S. P., Djulbegovic, B. & Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol. 5, 13 (2005).","journal-title":"BMC Med. Res. Methodol."},{"key":"21463_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1164\/rccm.201903-0541PP","volume":"200","author":"M Vasakova","year":"2019","unstructured":"Vasakova, M. et al. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am. J. Respir Crit. Care Med. 200, 301\u2013308 (2019).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"21463_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3904\/kjim.2016.212","volume":"32","author":"SM Koo","year":"2017","unstructured":"Koo, S. M. & Uh, S. T. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist\u2019s point of view. Korean J. Intern. Med. 32, 600 (2017).","journal-title":"Korean J. Intern. Med."},{"key":"21463_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir, G. J. et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19, 353\u2013359 (2014).","journal-title":"Respirology"},{"key":"21463_CR12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jbspin.2014.12.006","volume":"82","author":"F Iannone","year":"2015","unstructured":"Iannone, F. et al. Obesity reduces the drug survival of second line biological drugs following a first TNF-\u03b1 inhibitor in rheumatoid arthritis patients. Joint Bone Spine. 82, 187\u2013191 (2015).","journal-title":"Joint Bone Spine"},{"key":"21463_CR13","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jbspin.2015.02.011","volume":"82","author":"S Ottaviani","year":"2015","unstructured":"Ottaviani, S. et al. Body mass index and response to rituximab in rheumatoid arthritis. Joint Bone Spine. 82, 432\u2013436 (2015).","journal-title":"Joint Bone Spine"},{"key":"21463_CR14","doi-asserted-by":"publisher","first-page":"104109","DOI":"10.1016\/j.resp.2023.104109","volume":"315","author":"M Zielinski","year":"2023","unstructured":"Zielinski, M., Chwalba, A., Jastrzebski, D. & Ziora, D. Adipokines in interstitial lung diseases. Respir Physiol. Neurobiol. 315, 104109 (2023).","journal-title":"Respir Physiol. Neurobiol."},{"key":"21463_CR15","doi-asserted-by":"publisher","first-page":"10484","DOI":"10.1038\/s41598-019-46990-3","volume":"9","author":"N Enomoto","year":"2019","unstructured":"Enomoto, N. et al. Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis. Sci. Rep. 9, 10484 (2019).","journal-title":"Sci. Rep."},{"key":"21463_CR16","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00259-023-06143-1","volume":"50","author":"H Adams","year":"2023","unstructured":"Adams, H. et al. [89Zr]-Immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial. Eur. J. Nucl. Med. Mol. Imaging. 50, 1929\u20131939 (2023).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21463-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21463-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:29:03Z","timestamp":1760718543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21463-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21463-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36460"}}